Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Sun Pharmaceutical Industries Ltd.'s net profit margin of 20.8% in FY2025 reflects excellent profitability, with operating margin at 23.8% and gross margin at 79.6%.
In FY 2025, Sun Pharmaceutical Industries Ltd. posted a gross margin of 79.6%, an operating margin of 23.8%, a net margin of 20.8%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Sun Pharmaceutical Industries Ltd.'s revenue grew 5.5% to 525.78B and net profit grew 13.7% to 109.29B YoY in FY2025, indicating moderate business momentum.
In FY 2025, Sun Pharmaceutical Industries Ltd.'s revenue grew by 5.5% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Sun Pharmaceutical Industries Ltd.'s ROE of 15.1% in FY2025 indicates good shareholder returns.
In FY 2025, Sun Pharmaceutical Industries Ltd. reported an ROE of 15.1%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Sun Pharmaceutical Industries Ltd.'s FCF/NI ratio of 1.09x in FY2025 indicates solid earnings quality with FCF tracking net income.
In FY 2025, Sun Pharmaceutical Industries Ltd.'s free cash flow exceeded net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Sun Pharmaceutical Industries Ltd.'s OCF/NI ratio of 1.29x in FY2025 indicates sound cash management with earnings well-backed by cash.
In FY 2025, Sun Pharmaceutical Industries Ltd.'s operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Sun Pharmaceutical Industries Ltd.'s current ratio of 2.89x in FY2025 indicates healthy short-term liquidity.
In FY 2025, Sun Pharmaceutical Industries Ltd. reported a current ratio of 2.89. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Sun Pharmaceutical Industries Ltd.'s interest coverage ratio of 54.1x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Sun Pharmaceutical Industries Ltd. reported an interest coverage ratio of 54.1x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Sun Pharmaceutical Industries Ltd.'s debt-to-equity ratio of 0.03x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Sun Pharmaceutical Industries Ltd. reported a debt-to-equity ratio of 0.03. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Sun Pharmaceutical Industries Ltd.'s debt decreased 27.8% YoY in FY2025 — positive deleveraging improves financial flexibility.
In FY 2025, Sun Pharmaceutical Industries Ltd.'s total debt decreased by 27.8% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Sun Pharmaceutical Industries Ltd.'s diluted shares remained virtually unchanged in FY2025.
Over 2 years (FY2024–FY2025), diluted shares remained essentially unchanged at 2.40B.
In FY 2025, Sun Pharmaceutical Industries Ltd.'s diluted shares remained flat by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025